Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • Pazdur declines to announce candidacy for vacated FDA commissioner role
  • Regulatory

Pazdur declines to announce candidacy for vacated FDA commissioner role

BioSpace

FDA veteran Richard Pazdur outlined his priorities for the next FDA commissioner but stopped short of putting himself forward as a candidate to lead the agency at an RBC Capital Markets event on Tuesd

Read full story

pharminent May 20, 2026 (Last updated: May 20, 2026)

BioSpace

FDA veteran Richard Pazdur outlined his priorities for the next FDA commissioner but stopped short of putting himself forward as a candidate to lead the agency at an RBC Capital Markets event on Tuesd

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Pepaxti study supports use in wider myeloma population
Next: Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Related Stories

  • Regulatory

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

pharminent June 9, 2026
  • Regulatory

Pfizer’s Hympavzi secures FDA expanded indications for haemophilia

pharminent June 9, 2026
  • Regulatory

Biogen’s salanersen gains FDA breakthrough therapy designation for SMA

pharminent June 5, 2026

You May Have Missed

  • M&A / Deals

Alzecure enters collaboration and with Lilly for Alzheimer’s project

pharminent June 9, 2026
  • Clinical Data

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

pharminent June 9, 2026
  • M&A / Deals

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

pharminent June 9, 2026
  • Regulatory

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

pharminent June 9, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.